One aspect of the present invention relates to spirocyclic compounds. Another
aspect of the present invention relates to the use of the spirocyclic compounds
as ligands for mammalian G-protein-coupled receptors or sigma receptors. The present
invention also relates to methods of modulating the activity of a G-protein-coupled
receptor or a sigma receptor in a mammal using the spirocyclic compounds of the
present invention. The present invention also relates to methods of treating various
diseases in a mammal using the spirocyclic compounds of the present invention.